Trupanion, Inc.
Q4 2020 Earnings Call Transcript

Published: 10 Feb 2021

[Operator:]

Greetings, and welcome to Trupanion Fourth Quarter 2020 Results Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. Please note, this conference is being recorded. I would now like to turn the conference over to your host, Laura Bainbridge, Vice President of Corporate Communications. Thank you. You may now begin.

[Laura Bainbridge:]

Good afternoon, and welcome to Trupanion's fourth quarter and 2020 year-end financial results conference call. Participating on today's call are Darryl Rawlings, Chief Executive Officer; and Tricia Plouf, and Margi Tooth, who were recently promoted to Co-Presidents. Similar to prior earnings calls, Margi will be joining Darryl and Tricia for the Q&A portion of today’s call.

[Darryl Rawlings:]

Thanks, Laura. Good afternoon. The fourth quarter capped off a strong year for Trupanion. Total revenue grew 31% over the prior year. Adjusted operating income totaled $57 million, up 29% over 2019. We invested approximately $44 million of these funds within our subscription business at an estimated internal rate of return of 41%. Our performance in 2020 is a testament to the consistency of our business model, the strength of our positioning in a large underpenetrated market, and the power of the pet. In 2020, against the backdrop of shock and uncertainty, pets reminded us of the importance of unconditional love. For my Zoom screen to yours, pets were everywhere this past year, and not just new pets to the household.

[Tricia Plouf:]

Thanks, Darryl, and good afternoon, everyone. As Darryl covered some of our 2020 financial highlights, I'll focus the majority of my commentary on our fourth quarter performance. I will also provide our outlook for the first quarter and full year of 2021. I echo Darryl sentiment that it was a strong quarter for Trupanion. Our outperformance was driven by an acceleration in net pet growth within our subscription business and continued strong performance within our other business. Total revenue for the quarter was $142.7 million, up 35% year-over-year. Within our subscription business, revenue was $106.4 million in the quarter, up 23% year-over-year. Total enrolled subscription pets increased 17% year-over-year to approximately 578,000 pets as of December 31. Average monthly retention which is calculated on a trailing 12-month basis was 98.71% compared to 98.58% in the prior year period. The improvement in retention extended the average pets life with Trupanion by approximately 8 months, and is impactful to our calculation of lifetime value and internal rate of return when we look at the unit economics of a single average pet. The increase over the prior year can be attributed to our improved service levels, a focus we spoke about on our last call and have continued through the year. Monthly average revenue per pet for the quarter was $62.03, an increase of 6% year-over-year. In local currency, U.S ARPU increased 6% and Canadian ARPU increased 4% over the prior year period. We are pleased to deliver continued acceleration and ARPU growth in the quarter, which reflects progress on our pricing initiatives, particularly in the second half of the year. Our subscription cost of revenue includes the cost of paying veterinary invoices and variable expenses. The cost of paying veterinary invoices for our subscription business was 71% of revenue during the quarter. Variable expenses remained consistent with the prior year at 9% of revenue, as we continue to focus on the member experience. Subscription gross margin was 20% of revenue in the quarter compared to 19% in the prior year period, and within our annual target of 18% to 21%. Our other business segment is comprised of revenue from other products and services that generally have a B2B component and different margin profiles than our subscription business. This now includes revenue from the sale of software solutions. In the fourth quarter, we completed a strategic acquisition of a software company that was predominantly focused on improving our back end processes and adding talent, but also had a small P&L impact. In total, other business revenue was $36.3 million for the quarter, an increase of 92% year-over-year. Growth in the number of pets enrolled and products within this segment, increased revenue 87% year-over-year. Additionally, the sale of software solutions contributed 6% to the growth of other revenue.

[Darryl Rawlings:]

Thanks, Trish. 2020 was a year unlike any other. The team navigated through a period of unprecedented change and came together in support of every veterinarian and pet owner who placed their trust in Trupanion. For this, I want to say thank you to the team. Look forward to seeing what we can accomplish together in 2021. With that, Margi, Trish and I are available for questions.

[Operator:]

Our first question is from Mark Argento with Lake Street Capital Markets. Please proceed.

[John Godin:]

Hi, everyone. This is John on for Mark. I appreciate you taking my question. First of all, just kind of looking back at the past year, maybe could you break out some of the areas where you've seen the highest returns on capital for investments. And if any of that has changed, kind of since the pandemic started?

[Darryl Rawlings:]

Hi, John. We don't break down kind of the categories of our internal rates of return neither by channel or by pet or geography. But what I can say is that we saw increased leads and conversion rates across the board, and particularly in the back half of the year.

[John Godin:]

Fair enough. Then second question, I know you guys have put a pretty big focus on the customer experience over the past couple quarters and really ramping that up. Has -- I know it would be early, but has that translated into any kind of data points or takeaways as far as your goals for nirvana in certain markets?

[Darryl Rawlings:]

Yes. We first started talking about this in Q2, and Q3, where the output of the metric that we're looking at is improved retention rates. And then you talk about nirvana, which is when existing pets -- our existing members add paths or tell their friends and if that can offset the amount of pets that are cancelling. During the year, we had more markets than ever hit that benchmark and we'll talk more details about that at the upcoming shareholder meeting. But we are definitely investing more dollars in our customer experience. So it really breaks down into kind of two areas. One is either educating the client at the time or before they enroll, or shortly after, and some of those funds shopping or pet acquisition costs. The other area is about really trying to improve our customer experience from the speed of answering the phones to our 24/7 365 service. And we're investing in areas such as technology, getting our software, more places, more automation. The recent software acquisition that Tricia mentioned, are all areas that we're investing, and we're also adding the bodies and people around to make sure that we can continue to try to increase those service levels. The only challenge that you can expect is with accelerated growth. Trying to keep up those operational excellence is a big task, but we are kind of investing to try to make that happen.

[Tricia Plouf:]

Yes, I will just add a couple of things, John. I think, as Darryl said, the main thing was the member experience that we're really trying to keep the momentum going with retention and how that can impact our results. And so that's a big focus for us. And we want to invest more dollars in the member experience, whether it's the claims experience, or also just the general experience that our team provides. And so, in the guidance, it contemplates -- for our subscription business for adjusted operating income, closer to 14% for the year rather than our target of 15. And that's the reason why is that focus on the member experience. And that's really, what we've learned in 2020 is that if we focus on it, we can see results like retention. And so we really want to double down on that going into 2021. And that -- and that's driving some of those numbers as this will be a big focus for us and to keep this momentum going. And then the other thing, Darryl mentioned slightly, and it's also a key takeaway of Q4. And some of the investments that we made is technology, scalability, the main way we have a great number of experience long-term through technology, through more automation and we're investing in that area as well.

[John Godin:]

Okay. That's helpful. Thank you guys and congrats on the nice quarter and year.

[Darryl Rawlings:]

Thanks, John.

[Operator:]

Our next question is from Maria Ripps with Canaccord. Please proceed.

[Maria Ripps:]

Good afternoon, and thanks for taking my questions. And Trish, Margi, congrats in your expanded roles. First, can you please expand on this new product initiatives that you mentioned and what are those investments and how should we think about sort of any revenue related to that?

[Darryl Rawlings:]

Yes, we first started talking about this, Maria, at our shareholder meeting last year. And you can expect more details in the upcoming shareholder letter and the following shareholder meeting. As the category expands, as you know, we really spent the first 20 years of the company trying to get to operating scale. We've built a lot of foundation. Foundation around our data, foundation around our national sales force, we call territory partners, investing in our customer experience to be the only company able to pay hospitals directly at the time of service. And when we look out the next 5, 10, 15 years, additional growth channels that we're going to be exploring are expanding out into other international markets. It's going to be adding new products that are designed specifically for new distribution channels. The acquisition of the software company will help us take advantage of those areas. But in 2021, the guidance that Tricia provided really doesn't anticipate any of those having any material impact on our P&L, in 2021 and 2022 and '23, we will start to see it. But really, these are long-term investments.

[Maria Ripps:]

Got it. That's very helpful. And then secondly, if we look at your full year outlook for subscription, which is -- which implies 25%, I think. Can you maybe give us some color in terms of what do you expect for pet growth versus ARPU expansion? And I believe last quarter, you mentioned that you may need to grow ARPU above your sort of normal 5-ish percent range. Can you maybe share with us where you are in that sort of price initiative process? And where they have all the necessary regulatory considerations in place for price increases?

[Tricia Plouf:]

Sure. Thanks for the question, Maria. Yes, I mean, pricing is something that we are constantly monitoring, and making sure is as accurate as possible. As we've talked about previously, we really try to price as granular as possible down to the neighborhood level. And so that pricing particular at a neighborhood level is something that is continuous. We have a large team that focuses on that and we don't expect that to change. I would highlight that I think we did a good job in 2020. In pricing, and particularly in the second half of the year, moving pricing up closer to 6% versus 5%. And we expect that to continue going in into 2021 and we'll remain focused on it. As we've mentioned before, in general, our historical ARPU increases over the past 10 years have been 5% to 6%. With some of the things, corporate consolidation and other pricing trends that we see in this space. We think, really, we should be in the foreseeable future, targeting closer to 6% to 7%. And our initiatives and kind of analysis of the data is focused on that, so that we can be as accurate as possible. The guidance in projects that's being closer to 6%, getting closer to 6% in 2021. And then the remainder obviously, comes from pet growth as well as some resemblance. We're not projecting dramatic improvements in retention. But we're obviously have a lot of initiatives to do that. But we haven't pre-baked those into our guidance. So it's really maintaining that retention momentum that we currently have.

[Maria Ripps:]

Got it. Thank you both.

[Operator:]

Our next question is from David Westenberg with Guggenheim Securities. Please proceed.

[David Westenberg:]

Hi. Thank you for taking my question and congrats on a great year here. Can you help us reconcile new patient growth at the veterinary clinic? I know you mentioned that, new pets was around 13 million versus lost pets at around 12. I am curious because kind of industry data says new patient growth is accelerating or has been quite robust at the practice. And I'm just wondering if that maybe helped you in the year and how to maybe think about that reconciled with, of course, pet adoption. Does that make sense?

[Tricia Plouf:]

It does make sense. Hi, Dave. So in terms of the data that we see while the traffic is definitely up in the veterinary industry, in general, there is, as we mentioned -- as Darryl mentioned in his remarks, most of those coming through people visiting as opposed to new pets going in. The bulk of the change that you see there is people are at home with their pets during COVID. They're seeing issues with their pets, and are taking their pets to vet more frequently. So there's an increased visit pattern there. For us the way that reconciles with the data we're seeing is, naturally, as you're going into the pet more, you're having those conversations you're taking care. But the care of your pet and the veterinary channel for us is that kind of that call mode that really we've developed those relationships with those events over the years through our Territory Partner Network has allowed them to appreciate the value of high quality pet insurance. And so we think about that coupled with the increased conversation happening in the vet level, people pay more attention to their pet. The power of the pet in the household at times of crisis, they're taking better care of them as well as that slight increase that we see in new pets coming in, so puppies and kittens. Overall penetration rates in general, are going up slightly in markets. And we can see that but generally it's down to people taking better care of their pets n times of crisis.

[David Westenberg:]

Got it. So -- yes, no -- I got it. So it did help you in the quarter. But the help is because you target the veterinary channel and the veterinary channel itself was robust. Its more than the aggregate -- new aggregate pets. Okay. No, that’s …

[Margi Tooth:]

I would answer that as well. When you think about the industry in general having moved to curbside to see the VAT lead growth as strong as it was particularly promising and I think just reinforces that value of the relationship that we have there. Because curbside, as many of us know, is particularly challenging for the veterinary industry. But to appreciate the volume, the use of the insurance is really good.

[David Westenberg:]

Got it. And second questions for Trish and sorry, I missed it. I got a new phone and it's kind of cutting in and out. When you are giving guidance, I think you've said in previous calls, you do expect to increase ARPU 7% versus 6% historically. And I think you said in the commentary, though, again, it was cutting out a little bit, you are expecting retention rates to increase and new pets to grow up, I mean, new pet growth? So can you help me, is it indeed still that 7%, or still an increase in ARPU to kind of catch up to that 71% ratio is still something you're expecting? And should we expect any kind of -- or why should we not be a headwind to new pet growth with ARPU growing up? Thank you.

[Tricia Plouf:]

Yes, let me -- I'll try to cover everything. Let me know if I missed anything. But, yes, I mean, in general, based on what we see in trends and costs and what's going on in the industry and data, we ideally were executing very well and we're getting closer to ARPU increases of 7% year-over-year. Now keep in mind, this is increases where we need them and we're targeting that 71% value proposition as you mentioned. Historically, our increases have been between 5% and 6%. And so, we're targeting 7% over to be closer to where we need to be and say, kind of stay in that spot that we're targeting. The guidance includes 6%, because we won't get to a full year of 7%, immediately. So we're going from really a full year at 5% in 2020, and then moving the needle to get closer to 6% in 2021, with the target with the data we have right now being 7%. And I think Margi, do you want to talk about the growth side of it?

[Margi Tooth:]

Yes, happy to. So I think when we think about the headwinds, and new pay growth, and we look at our performance and the business over the past 12 months, believes that our conversion rates are up and our retention rate is up. All of that would suggest that, the value proposition the retention rates being as strong as they are taking into 17 months. So significant increase through the year means that there is value in the product and the product is doing what it needs to do. And so it'd be increase in ARPU does not present any headwind to us.

[David Westenberg:]

Great. Thank you so much.

[Operator:]

Our next question is from Jon Block with Stifel. Please proceed.

[Jonathan Block:]

Great. Thanks and good afternoon, everyone. Maybe the first one just -- as we think the 2021 and this might build on Maria's question earlier, but the gross adds are really strong in the quarter. We're calculating over 30% year-over-year in the quarter. They were less than 10% in the first half of 2020. And they're probably somewhere in between for 3Q. So just when we think about 2021, how do we think about the gross adds year-over-year is 20% plus a fair number. And then how about the cadence of that as the comps were dramatically different throughout 2020?

[Margi Tooth:]

Hi, Jon, I can kick this off. In terms of the sort of the flow that you saw back in 2020 with the difference in the courses, a lot of what was happening in that year, if you look back is we were doubling down and focusing on the things that we can control. In the middle of the year, the pet growth wasn't what we were focused on, it was member experience, making sure we can be there for our members when they needed us. Focusing on the veterinary experience, the partnerships, and so we deliberately decided to focus on the number as opposed to growing. We started gradually as COVID -- what became more of a normality, I suppose. We started to focus on it, okay, let's see how we can get that growth. How do we start to dip our toe back into the water as well as maintaining the focus on member, which we did and we did it very effectively, the team is very skilled and I think are increasingly skilled on the digital front, helping us to improve that conversion rate. As we look forward in 2021, in the cadence of growth, we expect to be somewhat consistent, continuing to drive lead volume where we can and conversion rate help where we can. And I'll hand over to Trish to speak specifically to the pet growth of the year and the 20% that you asked about.

[Tricia Plouf:]

Yes, yes, I'm just echoing, building on what Margi said, we expect good momentum going into the year and then consistency moving through. To your direct question, the year-over-year comps in Q1 and Q2 of last year are lower than the back half of the year. So we'll probably -- you'll see that in the growth rates as they model out, and then when we get further into the year, we can update if trends look to be a little different than the visibility we have now. To answer your question, yes, we’ve got definitely lower comps and then higher costs that'll impact that calculation.

[Jonathan Block:]

Okay. Thank you for that helpful. And then Trish the contribution, I might have missed you a little bit. The contribution from the acquisition in the quarter, if you can revisit that, what that was and what will the SaaS contribution be in 2021? I mean, the guide was ahead on revenues, but right in line with us on subscription revs. And I'm just curious the contribution from the acquisition full year in 2021, as well.

[Tricia Plouf:]

Yes, thanks for the question. And I'll just take a minute to really highlight this acquisition, because we're excited about it. We're excited to acquire, Aquarium Software is the name of the company. And the back end really systems that they can provide to us as well as solutions that can be sold externally. They're a great company and an excellent team. And we've been very happy so far to the contribution in the 2 months of this past quarter was small, about million of top line revenue, and about 300,000, in additional operating margin, and this is within the other business segment is the segment that it's classified in. In terms of strategy, our primary strategy is really to improve Trupanion back end system, build them out, so we can better -- our chances of being able to execute are much better with this team working with us and the solutions that they have. So a lot of the things that Darryl mentioned in terms of products and initiatives, we're excited about this software to support it. And so 2021 is primarily focused on getting all of this integrated, so that we can execute more fully. And also working with that team on the longer term strategy. But we do have some revenue and other contributions there. So in the other business segment, it's about 4% to 5% of the growth that segments revenue is projected to come from this business. With all of that in mind, and then obviously, modest adjusted operating income profitability, from there with the primary focus in 2021 being on our system.

[Jonathan Block:]

Okay, great. And last one for me, increasing ARPU, that’s the allowable spend to increase for pet acquisition, if you will. Retentions also improved a good amount. So really, you've had two levers on the LVP. Darryl, can retention improved further from here? You've gotten a very kind of a high bar, if you will, and it can improve further, especially in light of the accelerating gross adds? Or to your point, you've talked about higher year one churn in the past. We'd love to get your thoughts there. Thanks, guys.

[Darryl Rawlings:]

Yes, I mean, our lifetime value improved 25% year-over-year, which is a staggeringly high number for the average pet. In a normal situation where retention stays the same, the lifetime value of a pet would be going up about the same as ARPU. So around 6% or 7%/. Unless we're able to do increase the retention rates, and our retention rates moving from 70 to 78 months in the last year, it's created a new high water level for ourselves. The question is going to be can we sustain those with higher growth rates? We're making a lot of investments to try to do that. But to your ultimate question is, where can we go? I ultimately believe that we could get to 99% retention if we could execute perfectly. I think we have roadmaps on how to get there. I would not speculate in a model that we're going to get there anytime soon. But internally, I think that's where we think perfection would be. And we were going to put our money and resources behind the teams to try to achieve that. But don't expect it over the next couple of years with the accelerated growth if we can maintain the 98, 71 or the 78 months in 2021, that would be a really impressive result.

[Jonathan Block:]

Okay. I will take the rest offline. Thanks, guys.

[Operator:]

Our next question is from Andrew Cooper with Raymond James. Please proceed.

[Andrew Cooper:]

Thanks for the question, guys. Maybe just to go a little bit different way thinking about 2021. One of the things we've heard from a lot of peers in the animal health space, not necessarily insurance was about limited access to clinics. And so just as we think about the growth in 2020 and then looking at 2021, is there anything to consider in terms of Trupanion Express installations, potentially having been a little bit tougher to do this year, because you did have a little bit more limited access to those new clinics, whereas where you already had the software installed or stronger existing relationships, I think, is the assumption that maybe that's what drove more of the growth appropriate, and just how do we think about that going forward?

[Tricia Plouf:]

Yes. Hi, Andrew. It's a good question. So I would say if we look back in 2020, we did -- we obviously had a very strong year. And as you pointed out, one of the areas that we did slow down on was our install rate for our software. We are, as we look forward to 2021, what we've seen is an increase in usage of it. So those that had it really started to use it, and the adoption rate then sort of slow bottom there. There are a couple of ways in which that happens. One of them is naturally within the community. Veterinarians having conversations around, how do you deal with curbside, how do you deal with the phenomenon that we're going through today, but also for members having that experience, because it removes the burden on them and they can take care of their pets. So we are seeing, despite the natural hazards that you have with not being able to get into the clinic, hospitals also installing that is still a focus of the business. And it's something that we are driving hard to ensure that our member experiences there, because we know the benefit it gives us overall. So we've learned a lot from 2020. And we've got a lot of tactics in the pipeline to be exploring, how do you get that install rate higher in 2021. And one of the mystery word of mouth recommendation, which we're starting to see come through nicely. Darryl, anything else?

[Darryl Rawlings:]

No.

[Andrew Cooper:]

Great. That's helpful. And then, while it's already been asked, so maybe just a quick update. The Florida trial has been out in the market for a little while now. Do you feel like you're at the point, given that a lot of the churn typically happens in that first year? Do you feel like you're at the point where you've seen some results that give you confidence one way or the other? Anything to add about that program or potential other tweaks to a broader rollout of a little bit different plan or anything like that?

[Tricia Plouf:]

Yes, it's a great question. So on a broad level, we're always looking to improve and simplify what we have out there as a product. And our products are built for use in the veterinary hospitals and make sure it's as strong as simple as possible and can give the highest and broadest coverage, I'll go with a new product, see if we can have a product that's going to increase distribution, so increased lead volume, better conversion, increase in ARPU and therefore longer retention and higher lifetime value. We're seeing some positive signs. Our business is complicated, so it's not just a case of putting the product out there and letting it sit. We need to keep marketing on data. We don't have anything stable and long-term metric wise that we'd want to share at this point. But it has been just shy of a year, there'll be a year in March. We're encouraged by what we see. And it takes time to get it right, but as soon as we're in a position where we can share more about that, we'll do that. We just keep watching and monitoring it in the meantime.

[Andrew Cooper:]

Great. I'll stop there. Appreciate the questions.

[Operator:]

Our final question is from Greg Gibas with Northland Securities. Please proceed.

[Gregory Gibas:]

Hey, Darryl, Trish and Margi. Thanks for taking the questions. Sorry, if I missed this, but with respect to your guidance, what are your kind of thoughts or assumptions around that lead volumes, where they go from maybe Q4 levels? What are you expecting regarding lead volume growth from that channel?

[Darryl Rawlings:]

Well, when you talk about Q4, I mean, the big standout was not just the number of new pets that we enroll, but the net pet growth. At 71% year-over-year, net pet growth, it's a super high number. We saw increases in leads and conversions across the board. We also saw increases in retention. And as we go into the guidance of 2020, we expect continued growth in our leads and conversions from the back channel to existing members telling their friends. And we're going to be investing more dollars to try to maintain these higher retention rates. And we'll have to see how they play out during the year.

[Gregory Gibas:]

Okay, sounds good. I don't think we touched too much on this, but regarding the partnership with Aflac, how's that progressing? You mentioned previously that deal kind of taking a while to ramp to reach its full potential. So just wondering I guess for an updated timeline on when we'd see a noticeable impact from that partnership?

[Darryl Rawlings:]

Yes, well as a reminder, Aflac is now one of our largest shareholders with just under 10% ownership of the company. And we really look at it in -- there's two markets Aflac has a long, long history in Japan and we're going to be exploring, bringing Trupanion into Japan. And that's going to take us several years to do it. I can tell you overall, there's nothing in our guidance that implies any impact from Aflac in 2021. But in the North American side, I'll let Margi talk to that. She's closer to it than I am.

[Margi Tooth:]

Yes, thanks, Darryl. So really kind of when we think about the North American side, specifically in the U.S market, we've got three different stages. And we talk about time line. If I could, the first one that will be first to market will be direct-to-consumer. We wouldn't expect that to see have any impacts this year really particularly. So that would be just going straight on the aflac.com website. Beyond that, we then have two other markets, one of them would be leveraging the expertise and the power of Aflac as a partner from the relationships they have with the large and medium sized businesses through their technology and their broker infrastructure. They're working at launching something in 2022. It will be initially a soft launch and soft rollout to see kind of how does that work? What do we see from that? So maybe if we're successful, and we execute well, we'll see some small benefit from that in '22. And then in 2023, the third part of that core is looking at how do we go after the small businesses. They're working with the 20,000 strong Aflac army of agents, who work specifically with a small businesses across the American market, which we wouldn't be doing until 2023. So we have a very tiered release program. We're working really closely with a team, they're a great team, really good partnership and seeing some really good signs in terms of the roadmap and the skills. And I'm really kind of building on that core competency that we believe we have, which is developing the right product for the right channel with a partner that understands the work site benefits so well. So really encouraged by what we see early stages yet, but some sort of solid time line built out and developed.

[Gregory Gibas:]

Got it. That's helpful Margi. Last one for me, just relating to those pre-revenue initiatives. Trisha, I think you said it was $0.3 million in the quarter. So a pretty small at this point. But how much we expect those initiatives to increase going forward? And can you maybe talk about some of the bigger initiatives that fall in there?

[Tricia Plouf:]

Yes, I'll start high level and then I'll let Darryl or Margi, talk to the specific initiatives, if they want to highlight any. In general, this will ebb and flow every year as opportunities arise and timing of when things launch. With the partnership with Aflac, and other things ramping up, as we look to the next 5 years, and what we want to execute on, we're really starting to focus here. And one thing is we've spent a lot of time particularly the last 5 years, scaling the business, focusing on hitting margin targets. And now we have the opportunity to think more strategically and more broadly. And we have the funds available to invest in these initiatives. So that's really at the core of what we're doing. In the next year, that combined with the kind of the sales and marketing expense related to the other business, just typically not more than a million or so we expect to be in the $2 million to $5 million range. And part of it just depends on how quickly some of these timelines and products -- product development like Margi mentioned. How quickly they go from a big picture perspective, though, these new initiatives, we -- want to make sure they have the opportunity to generate when they launched 30% to 40%, internal rates of return, as well as targeting a 15% adjusted operating margin similar to our current subscription business. So we're looking at it through all those lenses. Anything to highlight, Darryl?

[Darryl Rawlings:]

Yes. Just for the impact on the business, we don't need to be doing these for the next couple of years to hit our growth goals. But we're making these investments to think about making meaningful impacts to our P&L in the 5, 10, 15 year range. And they include international expansion, working with distribution partners where they can be powered by Trupanion. Meaning they got access to us paying hospitals directly, our data, the same value proposition, but as designing specific products that meet the need for those distribution channels. And we just see a lot of opportunity ahead of us and we're going to be planting those seeds over the next couple of years, because we've now broken it out into the P&L. Over the next year or two, we'll be able to start to talk about what those short-term investments look like and why we're making those investments. I look forward to my shareholder letter in April to provide more. But long-term, we would expect that they're going to act more like a subscription business with 15% margin targets and 30% to 40% internal rate of returns.

[Gregory Gibas:]

Great. That's helpful. Thank you.

[Operator:]

And that does conclude today's conference. You may disconnect your lines at this time and thank you for your participation.